Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies

European Journal of Haematology

Volumn 82, Issue 3, 2009, Pages 184-193

  Pulini, Stefano ^a   Rupoli, Serena ^b   Goteri, Gaia ^b   Pimpinelli, Nicola ^c   Alterini, Renato ^c   Bettacchi, Alberta ^d   Mulattieri, Simonetta ^b   Picardi, Paola ^b   Tassetti, Angela ^e   Scortechini, Anna Rita ^b   Fioritoni, Giuseppe ^a   Leoni, Pietro ^b  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Division of Dermatology   (Italy)

^e Division of Internal Medicine   (Italy)

Author keywords

Monochemotherapy; Pegylated liposomal doxorubicin; Primary cutaneous B cell lymphomas; Primary cutaneous lymphomas

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; PREDNISONE; PYRIDOXINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROLOGY; SKIN BIOPSY; SKIN LYMPHOMA; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; SKIN NEOPLASMS;

EID: 58849138775     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01197.x     Document Type: Article

References (49)

1. Charrois GJ, Allen TM. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003 306 : 1058 67.
2. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 2004 16 : 94 7.
3. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 25 : 3892 901.
4. Di Bella NJ, Khan MM, Dakhil SR, Logie KW, Marsland TA, Weinstein RE, Mirabel MY, Asmar L. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study. Clin Lymphoma 2003 3 : 235 40.
5. Avilés A, Neri N, Castañeda C, Talavera A, Huerta-Guzmán J, González M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol 2002 19 : 55 8.
6. Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, San Miguel JF. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002 87 : 822 7.
7. Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris MP, Vassilakopoulos T, Pangalis GA. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 2002 22 : 1845 8.
8. Visani G, Guiducci B, D'Adamo F, et al. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2005 46 : 477 9.
9. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006 47 : 2174 80.
10. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007 18 : 1071 9.
11. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 85.
12. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003 98 : 993 1001.
13. Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IV B mycosis fungoides. Br J Dermatol 2005 153 : 183 5.
14. Lybaek D, Iversen L. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol 2006 86 : 545 7.
15. Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007 92 : 686 9.
16. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 2008 144 : 727 33.
17. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007 143 : 1144 50.
18. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007 25 : 1581 7.
19. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, van Vloten WA, Meijer CJ, Willemze R. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999 17 : 2471 8.
20. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007 110 : 479 84.
21. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007 18 : 1159 64.
22. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000 136 : 1475 80.
23. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008 8 : 21 32.
24. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 25 : 579 86.
25. Common Terminology Criteria for Adverse Events (CTCAE) version 3. Available at http://www.fda.gov/cder/cancer/toxicityframe.htm (last accessed date 9 August 2006).
26. Goteri G, Ranaldi R, Simonetti O, Capretti R, Menzo S, Stramazzotti D, Morichetti D, Offidani AM, Rupoli S, Leoni P. Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: no evidence of Borrelia burgdorferi association. Leuk Lymphoma 2007 48 : 2184 8.
27. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008 112 : 1600 9.
28. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004 22 : 634 9.
29. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol 2006 33 (Suppl. 1 47 51.
30. Cozzio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, Schärer L, Burg G, Dummer R. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma 2006 47 : 865 9.
31. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005 52 : 847 53.
32. Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006 155 : 1197 200.
33. Dang NH, Fayad L, McLaughlin P, et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 2007 138 : 502 5.
34. Dummer R, Hassel JC, Fellenberg F, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004 104 : 1631 8.
35. Maza S, Gellrich S, Assaf C, Beyer M, Spilker L, Orawa H, Munz DL, Sterry W, Steinhoff M. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. Leuk Lymphoma 2008 49 : 1702 9.
36. Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997 24 : 457 61.
37. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 2005 141 : 1139 45.
38. Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R Dutch Cutaneous Lymphoma Group. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007 143 : 1520 6.
39. Stanway A, Rademaker M, Kennedy I, Newman P. Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil. Australas J Dermatol 2004 45 : 110 3.
40. Kempf W, Dummer R, Schmid MH, Fritz T, Wüthrich B, Burg G. Intralesional cisplatin for the treatment of cutaneous B-cell lymphoma. Arch Dermatol 1998 134 : 1343 5.
41. Zackheim HS, Epstein EH Jr., Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990 22 : 802 10.
42. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005 106 : 2491 7.
43. Sarris AH, Braunschweig I, Medeiros LJ, et al. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol 2001 19 : 398 405.
44. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998 31 : 583 8.
45. Nagatani T, Miyazawa M, Matsuzaki T, Hayakawa H, Iemoto G, Kim ST, Baba N, Sugiyama A, Aihara M, Miyamoto H. A case of cutaneous B-cell lymphoma treated successfully with MACOP-B. J Dermatol 1993 20 : 40 4.
46. Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol 2003 49 : 281 7.
47. Goto H, Nishio M, Endo T, Sato N, Koizumi K, Fujimoto K, Sakai T, Kumano K, Obara M, Koike T. Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma. Eur J Haematol 2005 74 : 526 8.
48. Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer 2000 89 : 913 9.
49. Van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, Steijlen PM, Dekker SK, van Vloten WA, Willemze R. Mycosis Fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000 136 : 504 10.